Ellis Martin Report: GT Biopharma, Inc. (NASDAQ:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen
The company is currently conducting a first-in-human Phase 1 clinical trial in acute myeloid leukemia (AML) and plans to expand into solid tumor indications, including breast, prostate, pancreatic, lung, bladder, ovarian, and head & neck cancers. GTB-5550 targets B7-H3, a protein highly expressed across a broad range of solid tumors.
During the interview, Mr. Breen also highlighted the potential application of the TriKE(R) platform in autoimmune diseases such as lupus, where immune system dysfunction plays a central role. The company anticipates filing a future IND to explore these indications.
With a platform-based approach and exposure to large addressable markets, GT Biopharma aims to position itself as a participant in the evolving immuno-oncology and immune modulation landscape.
To Listen to the Interview, please visit:
https://www.abnnewswire.net/lnk/I40FG026
About GT Biopharma, Inc.:
GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE) technology. TriKE therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
About The Ellis Martin Report:
The Ellis Martin Report (TEMR) and Money Talk Radio feature interviews with industry leaders in mining, biotech, energy, and technology. The program is globally syndicated through multiple financial platforms and streaming services.
Source:
GT Biopharma, Inc. The Ellis Martin Report
Contact:
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
NASDAQ: GTBP
GTBP Trading
37.97% G/L:
$0.44 Last:
8,878,967 Volume:
$0.374 Open:
